AL

Active Director Director DIN 08364625
DIN 08364625 First appointment Feb 2019 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2019
Shareholding value •••• Premium profile

About Amrit Lal

Data last updated:

Amrit Lal is a Director at Uencure Pharmaceuticals Private Limited (since 2019). The company operates in Chemicals. Uencure Pharmaceuticals Private Limited reported revenue of ₹23.3 Lakh (FY 2021).

DIN 08364625
Primary Designation Director
Industry Chemicals
First Appointment 15 Feb 2019
Oldest Company Age 7 yrs
Largest company Uencure Pharmaceuticals Private Limited · ₹23.3 Lakh (FY 2021)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director15 Feb 20192019₹23.3 Lakh (FY 2021)Active

Board colleagues of Amrit Lal

NameDINCompanyDesignation
Ankit Kumar08364624Uencure Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Uencure Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Amrit Lal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Amrit Lal

Amrit Lal currently holds 1 directorship: Uencure Pharmaceuticals Private Limited (Director, since 15 Feb 2019, revenue ₹23.3 Lakh (FY 2021)).

Amrit Lal was first appointed on 15 Feb 2019 as Director at Uencure Pharmaceuticals Private Limited.

The current boards of Amrit Lal's companies include Ankit Kumar (Uencure Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available